Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1172/JCI63248 http://scihub22266oqcxt.onion/10.1172/JCI63248 22484811!3337000!22484811     free     free     free       J+Clin+Invest 2012 ; 122 (5): 1605-8 Nephropedia Template TP {{tp|p=22484811|t=2012. Treating myeloma cast nephropathy without treating myeloma |pdf=|usr=}}{{22484811}} gab.com Text Treating myeloma cast nephropathy without treating myeloma JO: J Clin Invest http://www.kidney.de/pget.php?&tw=1&pmid=22484811 #FOAvip Cast nephropathy is the result of coprecipitation of immunoglobulin free light chains (FLCs) with Tamm-Horsfall glycoprotein (THP). It is a hallmark of multiple myeloma that has significant consequences. Treatment strategies in the past focused on reduction of serum FLC by control of the myeloma. In this issue, Ying et al. report on their successful synthesis of a cyclized competitor peptide that blocks the binding of FLC to THP. In animal studies, this cyclized peptide was capable of reducing cast formation and kidney injury, representing a novel treatment strategy for cast nephropathy that does not depend on the responsiveness of the myeloma to chemotherapy. Twit Text FOAVip Treating myeloma cast nephropathy without treating myeloma ????J Clin Invest http://www.kidney.de/pget.php?&tw=1&pmid=22484811 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=22484811 #FOAvip English Wikipedia <ref>{{Cite pmid|22484811}}</ref> Treating myeloma cast nephropathy without treating myeloma #MMPMID22484811 Leung N J Clin Invest 2012[May]; 122 (5): 1605-8 PMID22484811show ga Cast nephropathy is the result of coprecipitation of immunoglobulin free light chains (FLCs) with Tamm-Horsfall glycoprotein (THP). It is a hallmark of multiple myeloma that has significant consequences. Treatment strategies in the past focused on reduction of serum FLC by control of the myeloma. In this issue, Ying et al. report on their successful synthesis of a cyclized competitor peptide that blocks the binding of FLC to THP. In animal studies, this cyclized peptide was capable of reducing cast formation and kidney injury, representing a novel treatment strategy for cast nephropathy that does not depend on the responsiveness of the myeloma to chemotherapy. |Acute Kidney Injury/*prevention & control[MESH] |Animals[MESH] |Male[MESH]Treating myeloma cast nephropathy without treating myeloma (epmc).pdf DeepDyve Pubget Overpricing